OxyContin 80mg is a brand-name extended-release formulation of oxycodone hydrochloride, a potent opioid analgesic. The 80mg strength is one of the higher doses, typically prescribed for severe, chronic pain management (e.g., cancer pain or post-surgical recovery) in opioid-tolerant patients. It’s designed for 12-hour dosing to provide steady pain relief, not for immediate-release use like breakthrough pain.

Key Facts and Evidence

• Pharmacology: Oxycodone is a semi-synthetic opioid agonist binding to mu-opioid receptors in the brain and spinal cord, altering pain perception. The extended-release coating (abuse-deterrent formulation since 2010) uses a polymer matrix to slow dissolution, reducing crushing/snorting potential. Peak plasma levels occur ~3 hours post-dose; half-life is 4.5 hours (source: FDA prescribing info, Purdue Pharma).
• Dosing Guidelines (from FDA-approved label):

• 80mg specifics: Green-colored, round tablet (OP 80 imprint). Equivalent to ~120mg oral morphine daily when dosed BID. Not for children under 11 or <50kg.
• Clinical Efficacy: Studies (e.g., NEJM 2003 trial) show it reduces chronic pain scores by 30-50% in tolerant patients vs. placebo, but tolerance develops quickly (weeks).

Risks and Side Effects

High-strength doses like 80mg carry significant risks, substantiated by CDC data and FDA black-box warnings:

• Overdose: Respiratory depression is primary cause of death. Lethal dose ~200mg in naive users (equianalgesic calculators like CDC’s). Naloxone reverses it.
• Common Side Effects (>10% incidence): Constipation (40-60%), nausea (23%), drowsiness (23%), itching (15%).
• Serious Risks:

• Abuse Potential: Pre-2010 versions were crushed for rapid high (e.g., “oxy 80s” street value $40-80/pill, DEA reports). Reformulated version gels when crushed, but IV abuse still occurs.

Regulatory and Withdrawal Notes

• Controlled Substance: Schedule II (high abuse potential, DEA). Requires prescription; no refills without MD approval.
• Withdrawal: Abrupt stop causes flu-like symptoms (anxiety, sweats, diarrhea) peaking 72 hours. Taper 10-25% weekly (ASAM guidelines).
• Interactions: Potentiated by CYP3A4 inhibitors (e.g., ketoconazole); avoid with MAOIs.

Recent Context

Post-2010 reformulation reduced abuse rates by 75% (JAMA 2017), but contributed to the opioid crisis (e.g., Purdue’s $8B settlement, 2020). Alternatives: fentanyl patches, buprenorphine for maintenance.

Disclaimer: This is factual info from FDA, CDC, and peer-reviewed sources (e.g., PubMed). Not medical advice—consult a doctor for personal  Misuse can be fatal. If seeking treatment, resources like SAMHSA helpline (1-800-662-HELP) available.